Intellia Therapeutics Newsroom

AvenCell Raises $112 Million in Series B; Funding Led by Novo Holdings

PR Newswire18:00

Intellia Therapeutics' NTLA-2002 Shows Promise With Potential Stock Surge

TipRanksOct 21 19:45

Intellia Therapeutics, Inc. (NTLA) the Most Promising Biotech Stock According to Hedge Funds?

Yahoo FinanceOct 17 03:51

BMO Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $70

Futu NewsOct 16 19:34 · Ratings

Express News | Intellia Therapeutics Inc : Leerink Partners Cuts Target Price to $60 From $68

BreakingsOct 14 18:16

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

Intellia TherapeuticsOct 10 12:00

Intellia Therapeutics Inc (NTLA) Q2 2024 Earnings Call Highlights: Strategic Advances and ...

Yahoo FinanceOct 10 05:32

Cathie Wood's ARK Sheds Robinhood Stock, Adds to Amazon and Coinbase

InvestingOct 9 08:10

Truist Financial Maintains Intellia Therapeutics(NTLA.US) With Buy Rating

Futu NewsOct 8 19:33 · Ratings

Truist Financial Initiates a Buy Rating on Intellia Therapeutics (NTLA)

TipRanksOct 8 19:05 · Ratings

Intellia Therapeutics' Gene Editing Potential Bolsters Buy Rating Amidst Promising HAELO Study Progress

TipRanksOct 8 07:05

JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $41

Futu NewsOct 7 20:31 · Ratings

Intellia Therapeutics Launches Phase 3 Trial of Investigational Hereditary Angioedema Treatment

MT NewswiresOct 7 20:12

Express News | Intellia Therapeutics Announces Initiation of Haelo Phase 3 Study of Ntla-2002, an Investigational in Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (Hae)

BreakingsOct 7 19:30

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Intellia TherapeuticsOct 7 12:00

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireOct 4 04:01

Intellia Therapeutics (NASDAQ:NTLA Shareholders Incur Further Losses as Stock Declines 10% This Week, Taking Three-year Losses to 86%

Yahoo FinanceOct 3 23:21

Wells Fargo Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $95

Futu NewsOct 2 18:31 · Ratings

Institutional Owners May Consider Drastic Measures as Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Recent US$92m Drop Adds to Long-term Losses

Simply Wall StOct 2 01:22

Intellia Therapeutics to Present New Clinical Data From the Phase 1 Study of Nexiguran Ziclumeran (Nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions

GlobeNewswireOct 1 19:30